Background: The treatment with XeCl-excimer laser generated 308- nm UVB radiation has shown promising results in patients with vitiligo. Objective: In this controlled, prospective trial we studied the primary efficacy...Background: The treatment with XeCl-excimer laser generated 308- nm UVB radiation has shown promising results in patients with vitiligo. Objective: In this controlled, prospective trial we studied the primary efficacy (start and grade of repigmentation) and patient’ s satisfaction of XeCl-excimer laser for treatment of vitiligo patches at different body sites and re-evaluated the achieved repigmentation 12 months after the end of therapy. Methods: Twenty-five patients with generalized or localized vitiligo with a total of 85 lesions at different body sites were enrolled in this study. Vitiligo patches were treated with 308- nm XeCl-excimer laser 3 times a week for 6 to 10 weeks. The overall repigmentation grade of each treated lesion was evaluated once a week on a 5 point scale rating from 0 (no repigmentation), 1 (1- 5% ), 2 (6- 25% ), 3 (26- 50% ), 4 (51- 75% ), to 5 (76- 100% ). Results: Twenty-four patients completed the study. Within 6 to 10 weeks of treatment 67% of the patients (16/24) developed follicular repigmentation of at least one of their vitiligo lesions. Lesion repigmentation started after a mean of 13 treatments in lesions located on the face, trunk, arm, and/or leg (high-responder location), and after a mean of 22 treatments in lesions located on the elbow, wrist, dorsum of the hand, knee, and/or dorsum of the foot (low-responder location). Untreated control lesions and lesions located on the fingers did not achieve any repigmentation. After 10 weeks of treatment repigmentation of more than 75% was found in 25% (7/28) of lesions of the high-responder location group versus 2% (1/43) of lesions of the low-responder location group. In most cases, laser-induced repigmentation was persistent, as determined 12 months after the end of treatment. Conclusions: 308- nm excimer laser is an effective modality for the treatment of vitiligo. However, similar to other non-surgical treatment modalities, the therapeutic effect is mainly dependent on the location of vitiligo lesions.展开更多
目的:观察川芎清脑颗粒治疗慢性偏头痛的临床疗效和安全性。方法:采用多中心、随机、双盲、安慰剂对照、前瞻性试验设计,纳入偏头痛病人214例,采用数字随机表法分为川芎清脑颗粒治疗组(治疗组,n=107)和安慰剂对照组(对照组,n=107),服药4...目的:观察川芎清脑颗粒治疗慢性偏头痛的临床疗效和安全性。方法:采用多中心、随机、双盲、安慰剂对照、前瞻性试验设计,纳入偏头痛病人214例,采用数字随机表法分为川芎清脑颗粒治疗组(治疗组,n=107)和安慰剂对照组(对照组,n=107),服药4周,比较两组病人服药4周和停药4周时的头痛评分,采用疼痛数字评分法(numeric rating scales, NRS)、头痛月发作次数,记录药物的不良反应。结果:两组病人治疗前头痛的NRS评分和头痛月发作次数无明显差异(P> 0.05)。治疗组服药4周时的头痛NRS评分明显低于治疗前基础值(3.75 vs. 4.49,P <0.05),头痛月发作次数明显少于治疗前(2.80 vs. 7.51, P <0.001);停药4周时,头痛NRS评分进一步降低,明显低于服药4周时的头痛NRS评分(1.65 vs. 3.75, P <0.001),头痛月发作次数也进一步降低,明显低于服药4周时(1.50 vs.2.80, P <0.001);对照组服药4周和停药4周时的NRS评分和头痛月发作次数较治疗前无明显变化(P> 0.05)。治疗组服药4周时的头痛NRS评分明显低于对照组(3.75 vs. 4.34,P <0.001),头痛月发作次数明显少于对照组(2.80 vs.6.09,P <0.001);停药4周时,治疗组的头痛NRS评分显著低于对照组(1.65 vs. 4.16,P <0.001),头痛月发作次数显著少于对照组(1.50 vs. 6.45,P <0.001)。服药过程中及停药后4周,两组病人的血常规、肝肾功、心电图均未见显著异常改变,未发生不良事件。结论:川芎清脑颗粒可明显降低轻中度偏头痛病人的疼痛程度和发作次数,无明显不良反应。展开更多
Objective: To evaluate the effect of acupuncture on reproductive outcome in patients treated with IVF/intracytoplasmic sperm injection (ICSI). One group of patients received acupuncture on the day of ET, another group...Objective: To evaluate the effect of acupuncture on reproductive outcome in patients treated with IVF/intracytoplasmic sperm injection (ICSI). One group of patients received acupuncture on the day of ET, another group on ET day and again 2 days later (i.e., closer to implantation day), and both groups were compared with a control group that did not receive acupuncture. Design: Prospective, randomized trial. Setting: Private fertility center. Patient(s): During the study period all patients receiving IVF or ICSI treatment were offered participation in the study. On the day of oocyte retrieval, patients were randomly allocated (with sealed envelopes) to receive acupuncture on the day of ET (ACU 1 group, n = 95), on that day and again 2 days later (ACU 2 group, n = 91), or no acupuncture (control group, n = 87). Intervention(s): Acupuncture was performed immediately before and after ET (ACU 1 and 2 groups), with each session lasting 25 minutes; and one 25- minute session was performed 2 days later in the ACU 2 group. Main Outcome Measure(s): Clinical pregnancy and ongoing pregnancy rates in the three groups. Result(s): Clinical and ongoing pregnancy rates were significantly higher in the ACU 1 group as compared with controls (37 of 95 [39% ] vs. 21 of 87 [26% ] and 34 of 95 [36% ] vs. 19 of 87 [22% ]). The clinical and ongoing pregnancy rates in the ACU 2 group (36% and 26% ) were higher than in controls, but the difference did not reach statistical difference. Conclusion(s): Acupuncture on the day of ET significantly improves the reproductive outcome of IVF/ICSI, compared with no acupuncture. Repeating acupuncture on ET day + 2 provided no additional beneficial effect.展开更多
近年来,心血管疾病（cardiovascular diseases,CVD）的发病率及死亡率逐年升高,发病年龄趋于提前,因此心血管疾病防治的研究备受关注.研究表明,血清低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDL-C）可以导致CVD的发生...近年来,心血管疾病（cardiovascular diseases,CVD）的发病率及死亡率逐年升高,发病年龄趋于提前,因此心血管疾病防治的研究备受关注.研究表明,血清低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDL-C）可以导致CVD的发生和发展,使用降脂类药物调节血清LDL-C的水平,即使降至1.8mmol/L以下,CVD的发生率仍然较高[1].这种心血管疾病剩余风险存在的原因之一可能与血清低水平的HDL-C有关.他汀类药物IVUS试验的前瞻性随机试验的荟萃分析表明[2],血清低水平的HDL-C是动脉粥样硬化性疾病的独立危险因素.然而,最近对血清HDL-C水平和动脉粥样硬化性心血管疾病的这种负相关关系提出了异议.近年来,血清HDL-C对心血管疾病的防治作用及机制已成为研究的热点,综述如下.展开更多
Objective: To evaluate the overall effect of assisted hatching (AH) on the implantation, pregnancy, and live birth rates in women undergoing intracytoplasmic sperm injection (ICSI)- cycles; and to determine the effect...Objective: To evaluate the overall effect of assisted hatching (AH) on the implantation, pregnancy, and live birth rates in women undergoing intracytoplasmic sperm injection (ICSI)- cycles; and to determine the effect of AH on the cytogenetic outcome (chromosomal constitution) of pregnancy.Design: Prospective, randomized study.Setting: Academic research environment.Patient(s): A total of 172 couples were enrolled in the study.Intervention(s): Assisted hatching was carried out on day- 3 ICSI embryos.Main Outcome Measure(s): Implantation, clinical pregnancy, and live birth rates; cytogenetic analysis of abortuses and umbilical cord blood samples from newborns.Result(s): Biochemical, clinical, and ongoing pregnancy rates were not significantly different between the AH and control groups.The implantation rate was higher in the AH group than in the control group (16% vs.8% ), especially in women aged ≥ 35 years.Postnatal umbilical cord blood samples were collected and cytogenetically analyzed from 39 live births (20 from the AH group, 19 from the control group).Two abnormal karyotypes were found (one AH, one control).There were seven spontaneous losses during the study interval.Six of the abortuses underwent cytogenetic study (five AH, one control), and four were found to have an abnormal karyotype (three AH, one control). Conclusion: We found that AH improves implantation rates of ICSI cycles and seems to be most effective in women aged ≥ 35 years.A larger sample size is needed to determine whether AH improves the take- home- baby rate.Assisted hatching did not affect the rate of chromosomal abnormalities in live births in this study.展开更多
文摘Background: The treatment with XeCl-excimer laser generated 308- nm UVB radiation has shown promising results in patients with vitiligo. Objective: In this controlled, prospective trial we studied the primary efficacy (start and grade of repigmentation) and patient’ s satisfaction of XeCl-excimer laser for treatment of vitiligo patches at different body sites and re-evaluated the achieved repigmentation 12 months after the end of therapy. Methods: Twenty-five patients with generalized or localized vitiligo with a total of 85 lesions at different body sites were enrolled in this study. Vitiligo patches were treated with 308- nm XeCl-excimer laser 3 times a week for 6 to 10 weeks. The overall repigmentation grade of each treated lesion was evaluated once a week on a 5 point scale rating from 0 (no repigmentation), 1 (1- 5% ), 2 (6- 25% ), 3 (26- 50% ), 4 (51- 75% ), to 5 (76- 100% ). Results: Twenty-four patients completed the study. Within 6 to 10 weeks of treatment 67% of the patients (16/24) developed follicular repigmentation of at least one of their vitiligo lesions. Lesion repigmentation started after a mean of 13 treatments in lesions located on the face, trunk, arm, and/or leg (high-responder location), and after a mean of 22 treatments in lesions located on the elbow, wrist, dorsum of the hand, knee, and/or dorsum of the foot (low-responder location). Untreated control lesions and lesions located on the fingers did not achieve any repigmentation. After 10 weeks of treatment repigmentation of more than 75% was found in 25% (7/28) of lesions of the high-responder location group versus 2% (1/43) of lesions of the low-responder location group. In most cases, laser-induced repigmentation was persistent, as determined 12 months after the end of treatment. Conclusions: 308- nm excimer laser is an effective modality for the treatment of vitiligo. However, similar to other non-surgical treatment modalities, the therapeutic effect is mainly dependent on the location of vitiligo lesions.
文摘目的:观察川芎清脑颗粒治疗慢性偏头痛的临床疗效和安全性。方法:采用多中心、随机、双盲、安慰剂对照、前瞻性试验设计,纳入偏头痛病人214例,采用数字随机表法分为川芎清脑颗粒治疗组(治疗组,n=107)和安慰剂对照组(对照组,n=107),服药4周,比较两组病人服药4周和停药4周时的头痛评分,采用疼痛数字评分法(numeric rating scales, NRS)、头痛月发作次数,记录药物的不良反应。结果:两组病人治疗前头痛的NRS评分和头痛月发作次数无明显差异(P> 0.05)。治疗组服药4周时的头痛NRS评分明显低于治疗前基础值(3.75 vs. 4.49,P <0.05),头痛月发作次数明显少于治疗前(2.80 vs. 7.51, P <0.001);停药4周时,头痛NRS评分进一步降低,明显低于服药4周时的头痛NRS评分(1.65 vs. 3.75, P <0.001),头痛月发作次数也进一步降低,明显低于服药4周时(1.50 vs.2.80, P <0.001);对照组服药4周和停药4周时的NRS评分和头痛月发作次数较治疗前无明显变化(P> 0.05)。治疗组服药4周时的头痛NRS评分明显低于对照组(3.75 vs. 4.34,P <0.001),头痛月发作次数明显少于对照组(2.80 vs.6.09,P <0.001);停药4周时,治疗组的头痛NRS评分显著低于对照组(1.65 vs. 4.16,P <0.001),头痛月发作次数显著少于对照组(1.50 vs. 6.45,P <0.001)。服药过程中及停药后4周,两组病人的血常规、肝肾功、心电图均未见显著异常改变,未发生不良事件。结论:川芎清脑颗粒可明显降低轻中度偏头痛病人的疼痛程度和发作次数,无明显不良反应。
文摘Objective: To evaluate the effect of acupuncture on reproductive outcome in patients treated with IVF/intracytoplasmic sperm injection (ICSI). One group of patients received acupuncture on the day of ET, another group on ET day and again 2 days later (i.e., closer to implantation day), and both groups were compared with a control group that did not receive acupuncture. Design: Prospective, randomized trial. Setting: Private fertility center. Patient(s): During the study period all patients receiving IVF or ICSI treatment were offered participation in the study. On the day of oocyte retrieval, patients were randomly allocated (with sealed envelopes) to receive acupuncture on the day of ET (ACU 1 group, n = 95), on that day and again 2 days later (ACU 2 group, n = 91), or no acupuncture (control group, n = 87). Intervention(s): Acupuncture was performed immediately before and after ET (ACU 1 and 2 groups), with each session lasting 25 minutes; and one 25- minute session was performed 2 days later in the ACU 2 group. Main Outcome Measure(s): Clinical pregnancy and ongoing pregnancy rates in the three groups. Result(s): Clinical and ongoing pregnancy rates were significantly higher in the ACU 1 group as compared with controls (37 of 95 [39% ] vs. 21 of 87 [26% ] and 34 of 95 [36% ] vs. 19 of 87 [22% ]). The clinical and ongoing pregnancy rates in the ACU 2 group (36% and 26% ) were higher than in controls, but the difference did not reach statistical difference. Conclusion(s): Acupuncture on the day of ET significantly improves the reproductive outcome of IVF/ICSI, compared with no acupuncture. Repeating acupuncture on ET day + 2 provided no additional beneficial effect.
文摘近年来,心血管疾病（cardiovascular diseases,CVD）的发病率及死亡率逐年升高,发病年龄趋于提前,因此心血管疾病防治的研究备受关注.研究表明,血清低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDL-C）可以导致CVD的发生和发展,使用降脂类药物调节血清LDL-C的水平,即使降至1.8mmol/L以下,CVD的发生率仍然较高[1].这种心血管疾病剩余风险存在的原因之一可能与血清低水平的HDL-C有关.他汀类药物IVUS试验的前瞻性随机试验的荟萃分析表明[2],血清低水平的HDL-C是动脉粥样硬化性疾病的独立危险因素.然而,最近对血清HDL-C水平和动脉粥样硬化性心血管疾病的这种负相关关系提出了异议.近年来,血清HDL-C对心血管疾病的防治作用及机制已成为研究的热点,综述如下.
文摘Objective: To evaluate the overall effect of assisted hatching (AH) on the implantation, pregnancy, and live birth rates in women undergoing intracytoplasmic sperm injection (ICSI)- cycles; and to determine the effect of AH on the cytogenetic outcome (chromosomal constitution) of pregnancy.Design: Prospective, randomized study.Setting: Academic research environment.Patient(s): A total of 172 couples were enrolled in the study.Intervention(s): Assisted hatching was carried out on day- 3 ICSI embryos.Main Outcome Measure(s): Implantation, clinical pregnancy, and live birth rates; cytogenetic analysis of abortuses and umbilical cord blood samples from newborns.Result(s): Biochemical, clinical, and ongoing pregnancy rates were not significantly different between the AH and control groups.The implantation rate was higher in the AH group than in the control group (16% vs.8% ), especially in women aged ≥ 35 years.Postnatal umbilical cord blood samples were collected and cytogenetically analyzed from 39 live births (20 from the AH group, 19 from the control group).Two abnormal karyotypes were found (one AH, one control).There were seven spontaneous losses during the study interval.Six of the abortuses underwent cytogenetic study (five AH, one control), and four were found to have an abnormal karyotype (three AH, one control). Conclusion: We found that AH improves implantation rates of ICSI cycles and seems to be most effective in women aged ≥ 35 years.A larger sample size is needed to determine whether AH improves the take- home- baby rate.Assisted hatching did not affect the rate of chromosomal abnormalities in live births in this study.
